Biotech - Drug Development
Biotechnology companies developing novel therapeutics across disease areas (excluding oncology-focused)
Rare Disease Therapeutics154
Neuroscience & CNS93
Immunology & Autoimmune82
Metabolic & Cardiometabolic44
Infectious Disease & Vaccines52
Clinical-Stage Platforms148
 LLY | Eli Lilly & Co. | Metabolic & Cardiometabolic | $1.0t | $1416.97 | +3.2% | 3.9M |
 JNJ | Johnson & Johnson | Immunology & Autoimmune | $0.6t | $274.04 | -0.7% | 5.5M |
 ABBV | ABBVIE INC. | Immunology & Autoimmune | $464.4b | $294.17 | +1.4% | 4.5M |
 MRK | Merck & Co., Inc. | Infectious Disease & Vaccines | $356.0b | $149.59 | +2.2% | 8.6M |
 AZN | AstraZeneca PLC | Metabolic & Cardiometabolic | $243.3b | $185.85 | +7.0% | 5.0M |
 TMO | Thermo Fisher Scientific, Inc. | Clinical-Stage Platforms | $242.1b | $695.13 | -1.8% | 1.6M |
 AMGN | Amgen Inc | Immunology & AutoimmuneRare Disease Therapeutics | $217.9b | $466.00 | +1.2% | 2.3M |
 GILD | Gilead Sciences Inc | Infectious Disease & Vaccines | $179.5b | $170.50 | +3.2% | 8.8M |
 PFE | Pfizer Inc. | Infectious Disease & Vaccines | $158.5b | $30.45 | +1.7% | 28.8M |
 VRTX | Vertex Pharmaceuticals Inc | Rare Disease Therapeutics | $127.9b | $553.72 | +3.5% | 2.3M |
 BMY | Bristol-Myers Squibb Co. | Immunology & Autoimmune | $124.9b | $62.40 | +1.8% | 8.3M |
 MRNA | Moderna, Inc. Common Stock | Infectious Disease & Vaccines | $75.9b | $221.40 | -0.5% | 7.7M |
 REGN | Regeneron Pharmaceuticals Inc | Immunology & Autoimmune | $75.7b | $928.00 | +13.3% | 2.5M |
 A | Agilent Technologies Inc. | Clinical-Stage Platforms | $47.3b | $174.06 | -3.5% | 2.2M |
 IQV | IQVIA Holdings Inc. | Clinical-Stage Platforms | $42.5b | $268.65 | -2.8% | 827.1K |
 WAT | Waters Corp | Clinical-Stage Platforms | $41.8b | $462.69 | -3.6% | 1.1M |
 BIIB | Biogen Inc. Common Stock | Neuroscience & CNS | $32.5b | $253.69 | +1.6% | 1.0M |
 ALNY | Alnylam Pharmaceuticals, Inc. | Rare Disease Therapeutics | $29.4b | $165.73 | -5.2% | 6.3M |
 ROIV | Roivant Sciences Ltd. Common Shares | Immunology & Autoimmune | $25.8b | $33.94 | -1.6% | 3.4M |
 WST | West Pharmaceutical Services, Inc. | Clinical-Stage Platforms | $25.7b | $412.81 | -1.0% | 837.2K |
 RPRX | Royalty Pharma plc Class A Ordinary Shares | Clinical-Stage Platforms | $25.5b | $67.33 | +1.9% | 4.0M |
 INSM | Insmed, Inc. | Rare Disease Therapeutics | $24.3b | $113.22 | +0.9% | 3.6M |
 INCY | Incyte Genomics Inc | Rare Disease Therapeutics | $23.4b | $120.42 | +3.1% | 2.2M |
 UTHR | United Therapeutics Corp | Rare Disease Therapeutics | $23.2b | $598.08 | +0.9% | 388.7K |
 RVTY | Revvity, Inc. | Clinical-Stage Platforms | $16.9b | $160.00 | -5.3% | 2.7M |
 MEDP | Medpace Holdings, Inc. Common Stock | Clinical-Stage Platforms | $16.7b | $645.97 | -3.8% | 157.6K |
 JAZZ | Jazz Pharmaceuticals, Inc. | Neuroscience & CNS | $15.3b | $208.50 | +4.0% | 944.3K |
 ASND | Ascendis Pharma A/S Ordinary Share | Clinical-Stage Platforms | $15.0b | $251.34 | -0.7% | 336.5K |
 NBIX | Neurocrine Biosciences Inc | Neuroscience & CNS | $14.6b | $142.81 | -0.1% | 850.7K |
 CRL | Charles River Laboratories International, Inc. | Clinical-Stage Platforms | $13.9b | $373.11 | -2.9% | 1.3M |
 SMMT | Summit Therapeutics Inc. Common Stock | Infectious Disease & Vaccines | $13.4b | $15.95 | -1.0% | 3.1M |
 BBIO | BridgeBio Pharma, Inc. Common Stock | Rare Disease Therapeutics | $13.1b | $74.65 | +6.0% | 5.1M |
 CORT | Corcept Therapeutics Inc. | Rare Disease Therapeutics | $12.6b | $86.32 | -5.6% | 1.2M |
 TWST | Twist Bioscience Corporation Common Stock | Clinical-Stage Platforms | $12.5b | $152.56 | -12.0% | 3.2M |
 ICLR | Icon Plc | Clinical-Stage Platforms | $12.5b | $211.19 | -2.0% | 2.4M |
 HALO | Halozyme Therapeutics, Inc. | Clinical-Stage Platforms | $12.5b | $131.54 | -0.2% | 1.1M |
 MDGL | Madrigal Pharmaceuticals, Inc. Common Stock | Metabolic & Cardiometabolic | $11.5b | $434.50 | -0.3% | 211.5K |
 TECH | Bio-Techne Corp. | Clinical-Stage Platforms | $11.4b | $72.70 | -0.0% | 2.2M |
 BMRN | BioMarin Pharmaceuticals Inc | Rare Disease Therapeutics | $11.1b | $58.53 | +1.8% | 1.7M |
 IBRX | ImmunityBio, Inc. Common Stock | Immunology & Autoimmune | $10.9b | $8.27 | -5.1% | 7.9M |
 AVTR | Avantor, Inc. | Clinical-Stage Platforms | $10.4b | $15.93 | -4.9% | 8.2M |
 RGEN | Repligen Corp | Clinical-Stage Platforms | $10.3b | $176.94 | -6.3% | 4.2M |
 APGE | Apogee Therapeutics, Inc. Common Stock | Immunology & Autoimmune | $10.2b | $135.09 | 0.0% | N/A |
 BRKR | Bruker Corporation | Clinical-Stage Platforms | $9.6b | $57.15 | -7.9% | 1.6M |
 KRYS | Krystal Biotech, Inc. Common Stock | Rare Disease Therapeutics | $9.5b | $332.33 | +2.3% | 216.4K |
 AXSM | Axsome Therapeutics, Inc | Neuroscience & CNS | $9.4b | $146.56 | +0.8% | 1.9M |
 QGEN | QIAGEN N.V. | Clinical-Stage Platforms | $9.2b | $50.93 | -0.2% | 4.0M |
 CYTK | Cytokinetics Inc. | Rare Disease TherapeuticsNeuroscience & CNS | $9.1b | $63.50 | -0.4% | 898.4K |
 ARWR | Arrowhead Research Corporation | Rare Disease Therapeutics | $9.1b | $59.41 | -1.0% | 914.0K |
 PTGX | Protagonist Therapeutics, Inc | Immunology & AutoimmuneMetabolic & Cardiometabolic | $9.1b | $144.90 | +0.3% | 202.2K |